Patents by Inventor Hergen Spits

Hergen Spits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Anti-CD9 Antibody
    Publication number: 20190023803
    Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Applicant: AIMM Therapeutics B.V.
    Inventors: Hergen SPITS, Paula Maria Wilhelmina VAN HELDEN, Remko SCHOTTE, Wouter POS, Christien FATMAWATI, Danïel Michiel GO, Koen WAGNER, Julien Christian VILLAUDY
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS
    Publication number: 20180371410
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: August 28, 2018
    Publication date: December 27, 2018
    Inventor: Hergen SPITS
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20180327484
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Means and methods for influencing the stability of cells
    Patent number: 10077427
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: September 18, 2018
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventor: Hergen Spits
  • RSV-specific binding molecules and means for producing them
    Patent number: 10059757
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • AML ANTIGENS AND USES THEREOF
    Publication number: 20180170998
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina van HELDEN, Wouter POS
  • Means and methods for producing high affinity antibodies
    Patent number: 9969795
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: May 15, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 9822339
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 21, 2017
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • INFLUENZA A VIRUS SPECIFIC ANTIBODIES
    Publication number: 20170313766
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Inventors: Hergen SPITS, Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Arjen Quirinus BAKKER
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS
    Publication number: 20170306293
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 26, 2017
    Inventors: HERGEN SPITS, FERENC A. SCHEEREN, TIM BEAUMONT, SEAN A. DIEHL
  • Influenza A virus specific antibodies
    Patent number: 9718874
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • MEANS AND METHODS FOR DETERMINING T CELL RECOGNITION
    Publication number: 20170160269
    Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.
    Type: Application
    Filed: June 5, 2015
    Publication date: June 8, 2017
    Inventors: Carsten Linnemann, Laura Bies, Marit Martha van Buuren, Antonius Nicolaas Maria Schumacher, Hergen Spits, Remko Schotte
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20170009205
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: December 24, 2014
    Publication date: January 12, 2017
    Inventors: Pauline Maria Wilhelmina VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen SPITS, Tim BEAUMONT
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20160326261
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 10, 2016
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah Hazenberg
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20160244509
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 25, 2016
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES
    Publication number: 20160194382
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Application
    Filed: February 19, 2016
    Publication date: July 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER
  • RSV-specific binding molecules and means for producing them
    Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES
    Publication number: 20160096881
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Application
    Filed: December 2, 2015
    Publication date: April 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER, Koen WAGNER
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS
    Publication number: 20160060598
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: August 26, 2015
    Publication date: March 3, 2016
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • Means and methods for producing high affinity antibodies
    Patent number: 9273118
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: March 1, 2016
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Hergen Spits, Mark J. Kwakkenbos, Adrianus Q. Bakker